NEUROBLASTOMA

This early-phase trial tests a new treatment called GD2 CAR T cells in 12 children and teens (ages 1-16) with neuroblastoma that has come back or not responded to standard therapy. The treatment involves taking a patient's own immune cells, modifying them in a lab to better recog…

This early-stage trial tests a personalized treatment for children with recurrent neuroblastoma or newly diagnosed DIPG, two aggressive cancers. The approach combines targeted drugs with a custom-made immune therapy using the child's own cells, including dendritic cells, immune c…

This early-phase study tests a three-drug combination (sorafenib, cyclophosphamide, and topotecan) in children and young adults with neuroblastoma that has come back or not responded to treatment. The main goal is to find the safest dose of sorafenib when given with the other two…

This early-phase study tests a personalized cell therapy for children and young adults (up to age 26) with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, modified to recognize and attack a protein called B…

This early-stage trial tests a new drug, LY3295668 erbumine, in children whose neuroblastoma has returned or not responded to treatment. The main goal is to check safety and find the right dose, either alone or with other drugs. About 71 participants will take part. This is not a…

This study tests whether adding two chemotherapy drugs (irinotecan and temozolomide) to the standard immunotherapy regimen (dinutuximab, GM-CSF, and isotretinoin) can safely prevent high-risk neuroblastoma from returning after intensive initial therapy. About 41 children and youn…

This early-phase study tests a new combination of three drugs (radioactive therapy, an immunotherapy, and a checkpoint inhibitor) in children whose neuroblastoma has come back or not responded to treatment. The main goal is to see if the combination is safe and tolerable. About 4…

This early-stage study tests a new kind of cell therapy for children whose neuroblastoma has come back or not responded to standard treatment. Researchers take the child's own immune T cells, add genes to help them recognize and attack neuroblastoma cells, and also include a safe…

This early-phase study tests an experimental drug called CLR 131 in 30 children, adolescents, and young adults whose solid tumors, lymphoma, or brain tumors have returned or not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Par…

This early-stage study tests a flavored, drinkable chemotherapy called VAL-413 (Orotecan) combined with another drug (temozolomide) in children and young adults up to age 30 whose solid tumors have come back. The main goal is to find the safest dose and see how the body processes…

This study tests a combination of an antibody (Hu3F8) and a growth factor (GM-CSF) in children with high-risk neuroblastoma that has come back or not responded to standard treatment. The goal is to find the safest dose and see how the body handles the therapy. 186 participants ar…

This early-stage study tests a personalized cell therapy for children and young adults (ages 1–30) with solid tumors that have come back or not responded to treatment. The therapy uses the patient's own immune cells, modified to recognize and attack tumors that carry a protein ca…

This study tests whether adjusting treatment based on each child's tumor biology and how the tumor responds can reduce side effects while still controlling the disease. About 621 children with non-high-risk neuroblastoma are being observed or given tailored therapy instead of sta…

This early-stage trial tests a new combination treatment for children with neuroblastoma that has come back or not responded to standard therapy. It uses the child's own natural killer (NK) cells, grown in a lab, along with an antibody drug (dinutuximab) and sometimes a drug call…

This early-stage study tests a new treatment for advanced osteosarcoma and neuroblastoma that has not responded to standard therapies. Researchers take a patient's own immune cells, add a special receptor to help them recognize and attack cancer cells, and combine them with a chi…

This study tested whether a fecal microbiota transplant (FMT) could improve standard treatment for neuroblastoma by fixing an imbalance in gut bacteria. Only one child with neuroblastoma and a specific gut bacteria gap was eligible. The goal was to see if correcting the microbiom…

This study tests a new radioactive tracer called 18F-DA for PET scans to see if it can find neuroblastoma and pheochromocytoma tumors more clearly than the current tracer. About 20 children and adults with known or suspected tumors will receive the tracer and be monitored for sid…

This study tests whether a special PET/CT scan using a radioactive tracer called 68Ga-DOTATATE can better detect neuroendocrine tumors (like neuroblastoma) in children and young adults up to age 30. The scan is compared to the standard MIBG scan to see which one more clearly show…

This study looks at whether a special PET scan using a natural substance called methionine can help doctors see tumors in children and young adults with cancer. About 500 participants will get the scan to check if it can find tumors, tell how aggressive they are, and tell leftove…

This study looks at whether a drug called dinutuximab, used to treat high-risk neuroblastoma in children, can be given safely in 4 hours or less instead of the usual 10-20 hours. Eleven children with relapsed or hard-to-treat neuroblastoma will receive the faster infusion. If suc…

This study searches for brand-new gene changes that appear in a person with cancer but not in their parents. By comparing cancer patients, their healthy parents, and other family members, researchers hope to uncover genetic clues that raise cancer risk. The goal is to better iden…

This study looks at tumor samples from 93 children and young adults with neuroblastoma that has come back or not responded to treatment. The goal is to find specific genetic changes or immune system markers that could guide future therapies. No new treatment is given; instead, re…

This study uses a radioactive antibody (124I-Hu3F8) and PET/CT scans to see how the antibody moves through the body and reaches tumors. Seven people with melanoma, neuroblastoma, or sarcoma will receive one injection and have multiple scans over several days. The goal is to under…